Rain Oncology Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 63

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $50M

Rain Oncology General Information

Description

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Contact Information

Formerly Known As
Rain Therapeutics
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 8000 Jarvis Avenue
  • Suite 204
  • Newark, CA 94560
  • United States
+1 (510)
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 8000 Jarvis Avenue
  • Suite 204
  • Newark, CA 94560
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rain Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 26-Jan-2024 $50M Completed Generating Revenue
5. PIPE 08-Nov-2022 Completed Generating Revenue
4. IPO 23-Apr-2021 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 12-Sep-2020 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 02-May-2018 $18.4M $19.4M Completed Startup
1. Seed Round 13-Dec-2017 $1M $1M Completed Startup
To view Rain Oncology’s complete valuation and funding history, request access »

Rain Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Rain Oncology’s complete cap table history, request access »

Rain Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for whic
Drug Delivery
Newark, CA
63 As of 2022

Princeton, NJ
 

New Taipei City, Taiwan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rain Oncology Competitors (9)

One of Rain Oncology’s 9 competitors is PMV Pharma, a Formerly VC-backed company based in Princeton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PMV Pharma Formerly VC-backed Princeton, NJ
Senhwa Biosciences Formerly VC-backed New Taipei City, Taiwan
Kartos Therapeutics Formerly VC-backed Redwood City, CA
Erasca Formerly VC-backed San Diego, CA
Rein Therapeutics Formerly VC-backed Austin, TX
You’re viewing 5 of 9 competitors. Get the full list »

Rain Oncology Patents

Rain Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021127456-A1 Methods of inhibiting epidermal growth factor receptor proteins Inactive 19-Dec-2019
WO-2020205627-A1 Use of biomarker in cancer therapy Inactive 29-Mar-2019
WO-2020102304-A1 Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same Inactive 13-Nov-2018
AU-2019338185-A1 Compounds, compositions and methods for treating or preventing her-driven cancers Inactive 04-Sep-2018
CA-3110658-A1 Compounds, compositions and methods for treating or preventing her-driven cancers Inactive 04-Sep-2018 C12Q1/6886
To view Rain Oncology’s complete patent history, request access »

Rain Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rain Oncology Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
Auckland UniServices Corporate Venture Capital Minority
BVF Partners Hedge Fund Minority
Boxer Capital Corporate Venture Capital Minority
Cormorant Asset Management PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Rain Oncology ESG

Risk Overview

Risk Rating

Updated September, 30, 2023

27.53 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view Rain Oncology’s complete esg history, request access »

Rain Oncology FAQs

  • When was Rain Oncology founded?

    Rain Oncology was founded in 2017.

  • Where is Rain Oncology headquartered?

    Rain Oncology is headquartered in Newark, CA.

  • What is the size of Rain Oncology?

    Rain Oncology has 63 total employees.

  • What industry is Rain Oncology in?

    Rain Oncology’s primary industry is Drug Delivery.

  • Is Rain Oncology a private or public company?

    Rain Oncology is a Private company.

  • What is the current valuation of Rain Oncology?

    The current valuation of Rain Oncology is .

  • What is Rain Oncology’s current revenue?

    The current revenue for Rain Oncology is .

  • How much funding has Rain Oncology raised over time?

    Rain Oncology has raised $274M.

  • Who are Rain Oncology’s investors?

    Adage Capital Management, Auckland UniServices, BVF Partners, Boxer Capital, and Cormorant Asset Management are 5 of 10 investors who have invested in Rain Oncology.

  • Who are Rain Oncology’s competitors?

    PMV Pharma, Senhwa Biosciences, Kartos Therapeutics, Erasca, and Rein Therapeutics are some of the 9 competitors of Rain Oncology.

  • When was Rain Oncology acquired?

    Rain Oncology was acquired on 26-Jan-2024.

  • Who acquired Rain Oncology?

    Rain Oncology was acquired by Pathos AI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process